Appendix A — Glossary

A reference list of recurring technical terms. Terms are linked from the text; each entry is intentionally brief, with fuller treatment in the relevant chapter. Entries are listed alphabetically.

A.0.1 AMP-activated protein kinase (AMPK)

A central energy sensor activated by a falling cellular energy charge (a rising AMP-to-ATP ratio); it promotes catabolism, mitochondrial biogenesis and autophagy, and its activation is associated with extended lifespan. The principal target of metformin.

A.0.2 Antagonistic hallmarks

The middle tier of the hallmarks of ageing — responses to damage that are beneficial at low intensity but harmful when chronic or excessive: deregulated nutrient-sensing, mitochondrial dysfunction and cellular senescence. Their dose-dependence means a sound therapy must recalibrate them, not abolish them.

A.0.3 Autophagy

The process by which a cell encloses its own worn or surplus components and delivers them to the lysosome for breakdown and recycling. Its main form is macroautophagy; specialised forms include mitophagy and chaperone-mediated autophagy. Autophagic capacity declines with age.

A.0.4 Biological age

The functional state of an organism’s tissues relative to others of the same species, as opposed to chronological age (time since birth). The quantity that ageing research seeks to measure and ageing medicine to lower. See Chapter 10.

A.0.5 Biomarker of ageing

A measurable quantity — molecular, physiological or functional — that reports an individual’s biological state relative to others of the same chronological age, and so estimates biological age. To serve in a trial it must additionally be responsive to intervention, a far stricter requirement than mere correlation with age. See Chapter 10.

A.0.6 Blastocyst complementation

The generation of a donor-derived organ by injecting pluripotent stem cells into a host embryo (blastocyst) genetically prevented from forming that organ; with the developmental niche left vacant, the donor cells fill it and build the missing organ. The basis of efforts to grow patient-matched organs in animals. See Chapter 9.

A.0.7 Brain–computer interface (BCI)

A device that records neural activity and translates it, in real time, into control of an external effector — text, synthesised speech, a cursor or a limb. Clinical BCIs are restorative, returning communication or movement to people with paralysis; the “enhancing” BCI of the transhumanist imagination remains unrealised. See Chapter 15.

A.0.8 Caloric restriction mimetic (CRM)

A compound that reproduces some of the physiological and molecular effects of dietary restriction — and its health and longevity benefits — without requiring a reduction in food intake, typically by acting on the nutrient-sensing network (for example rapamycin, metformin or spermidine).

A.0.9 Catastrophic health expenditure

Out-of-pocket health spending that exceeds a threshold share of a household’s resources (commonly 10% or 25% of total or non-food consumption), signalling that paying for care has displaced other necessary spending. Used in WHO methodology to measure financial hardship from health systems.

A.0.10 Chaperone

A protein (notably the heat-shock proteins) that assists the folding and refolding of other proteins and prevents their aggregation. Chaperone capacity, and the heat-shock response that scales it to demand, decline with age.

A.0.11 Cell fate determination

The progressive process during development by which a cell’s range of possible identities is narrowed until it is committed to one specialised type. The chosen fate is then held in place by the epigenome; much of this book treats ageing as the slow loosening of fates that development took great care to fix.

A.0.12 Cellular differentiation

The process by which an unspecialised cell acquires the form and function of a particular type — a neuron, a hepatocyte — switching on only the relevant part of its genome. Differentiation builds the body in development; its gradual blurring in later life underlies the loss of cellular identity that runs through this book.

A.0.13 Cellular senescence

A stable arrest in which a cell permanently stops dividing but does not die, often adopting an inflammatory secretory programme (the SASP). Distinct from organismal senescence (whole-body ageing). See Chapter 4.

A.0.14 Chimera

An organism whose tissues derive from two or more genetically distinct cell populations. In regenerative medicine, an animal carrying a donor-derived (potentially human) organ produced by blastocyst complementation; interspecies chimeras raise both the species-barrier problem and the ethical questions taken up in Chapter 14.

A.0.15 Compression of morbidity

The goal of confining illness and disability to a shorter window late in life, so that healthy years are extended even if total lifespan changes little.

A.0.16 Converging technologies (NBIC)

The anticipated convergence of nanotechnology, biotechnology, information technology and cognitive science into a single platform for intervening in the human organism. Invoked in the enhancement debate as the technical basis for capacities beyond the species-typical norm; in practice its best-evidenced products to date are restorative rather than enhancing. See Chapter 15.

A.0.17 Decellularisation

The removal of all cells from a donor tissue or organ, usually with detergents, leaving an intact extracellular-matrix scaffold — the native architecture, vasculature template and mechanical cues — to be repopulated with the recipient’s own cells.

A.0.18 Dedifferentiation

The reversion of a specialised cell to a less committed, more plastic state. A natural part of tissue regeneration and a danger in cancer, it is also the controlled aim — in brief, partial form — of cellular reprogramming.

A.0.19 Demographic transition

The historical sequence, observed in every industrialising society, in which death rates fall first and birth rates fall afterwards. In the interval between the two the population grows rapidly; once fertility settles below replacement level, the population ages and eventually contracts. The process is largely complete in high-income countries and still under way in those that industrialised more recently. See Chapter 12.

A.0.20 Deprivation account

The view, given canonical form by Thomas Nagel, that death harms the one who dies not as a state they endure but by depriving them of the goods they would otherwise have had. The modern counter to the Epicurean claim that death is “nothing to us”, and the premise on which extending healthy life counts as averting a harm.

A.0.21 Developmental (programmed) senescence

A beneficial, tightly controlled form of cellular senescence used by the embryo to sculpt tissues and clear away transient structures. Its existence shows that senescence is not merely a fault of ageing but an ancient developmental tool, later redeployed — for good and ill — in the adult body.

A.0.22 Dietary restriction (DR)

Reduced food intake without malnutrition; the most reproducible non-genetic intervention shown to extend lifespan in laboratory species. See Chapter 6.

A.0.23 Disability-adjusted life-year (DALY)

The standard unit of the global burden of disease, equal to the sum of years of life lost to premature mortality and years lived with disability, the latter weighted by severity. One DALY represents one lost year of healthy life. The measure allows mortality and morbidity to be compared and combined across diseases, ages and populations.

A.0.24 DNA methylation

The addition of a methyl group to cytosine bases of DNA, typically at CpG sites; methylation of promoter CpG islands generally silences the associated gene. Age-related change in methylation is the substrate of most ageing clocks.

A.0.25 Effect size

The magnitude of a difference between groups in a trial, separated from the question of whether that difference is statistically significant. Standardised forms (Cohen’s d, Hedges’ g, hazard or odds ratios) allow comparison across studies; the raw form is the difference in the units the study reports. A small effect can be statistically significant in a large enough trial and still be clinically meaningless; a large effect can fail significance in a small one and still matter.

A.0.26 Embryonic rejuvenation (“ground zero”)

The proposal that biological age is actively reset to a minimum at a defined point in early embryonic development — a “ground zero” — after which ageing begins afresh. It implies that a natural rejuvenation programme exists, and raises the question this book returns to: whether it can be partially re-enacted in adult cells.

A.0.27 Enhancement (vs therapy)

A medical or biological intervention that produces a capacity beyond the relevant baseline of normal human function, as distinct from therapy, which restores a capacity toward that baseline. Where the line falls depends on the framework: the normal-function account anchors it in species-typical statistics, while the welfarist account treats the distinction as morally inert once the welfare gains are equivalent. Enhancement is itself graded — moderate enhancement lies within or just past the normal range, radical enhancement significantly beyond the human maximum — a distinction that carries much of the argument about transhumanism. See Chapter 14 and Chapter 15.

A.0.28 Epigenetic clock

An estimator of biological age built from patterns of DNA methylation (or related marks) across the genome. See Chapter 3.

A.0.29 Epigenetic drift

The progressive, partly stochastic divergence of a cell’s epigenome from its youthful state — derepression of inappropriate genes, rising cell-to-cell variability and loss of identity. The manifestation of failing epigenetic fidelity.

A.0.30 Epigenetic fidelity

The reliability with which a cell’s interlocking chromatin systems preserve the correct pattern of gene expression across divisions and stresses. Its systemic breakdown is proposed as the unifying mechanism of epigenetic ageing.

A.0.31 Epigenetic reprogramming, developmental

The natural, genome-wide erasure and re-establishment of epigenetic marks in germ cells and the early embryo, which resets cellular identity each generation. This biological “factory reset” is the natural counterpart of the induced partial reprogramming explored here — and the reason ageing parents have young offspring.

A.0.32 Epigenome

The layer of chemical modifications to DNA and its associated proteins that controls which genes are active, without changing the underlying DNA sequence. The principal substrate of cellular identity — and, on the information theory, the substance lost in ageing.

A.0.33 Epithelial–mesenchymal transition (EMT)

A developmental programme in which stationary, tightly bound epithelial cells become mobile and mesenchymal-like. Essential in the embryo and in wound healing; implicated in fibrosis, cancer spread and, as mesenchymal drift, in ageing.

A.0.34 Exosome

A small extracellular vesicle (roughly 30–150 nm) of endosomal origin, carrying proteins, lipids and regulatory RNAs between cells; the vesicle class most often credited with the regenerative effects of stem-cell secretions.

A.0.35 Extracellular vesicle (EV)

A membrane-bound particle released by cells that ferries bioactive cargo — proteins, lipids and nucleic acids — to other cells; exosomes are the best-studied subclass. EVs are central to the paracrine action of stem cells and to cell-free regenerative therapies. See Chapter 9.

A.0.36 Fasting-mimicking diet

A periodic, low-calorie, low-protein dietary regimen designed to reproduce the metabolic effects of fasting — including the switch to ketone-body metabolism — while still providing some food.

A.0.37 Fibrosis

The accumulation of excess fibrous connective tissue (scarring) that stiffens and impairs organs; a common endpoint of chronic tissue damage and of ageing.

A.0.38 Gastrulation (gastrula)

The early embryonic process that reorganises a simple ball of cells into the gastrula, a layered structure containing the three germ layers from which all tissues form. It is the founding act of assigning cells their fates — the identity later maintained through life and, on this book’s argument, eroded in ageing.

A.0.39 Germ layers (ectoderm, mesoderm, endoderm)

The three primary cell layers laid down at gastrulation, the source of every tissue: ectoderm (skin and nervous system), mesoderm (muscle, bone, blood and connective tissue) and endoderm (the gut and internal organ linings). The mesodermal–mesenchymal programmes resurface pathologically in old age as mesenchymal drift.

A.0.40 Germline and soma (Weismann barrier)

The distinction between the germline, the lineage of reproductive cells that carries information to the next generation, and the soma, all the body’s other cells. Because natural selection acts mainly through the germline, the soma is evolutionarily “disposable” — the deep reason it ages while the germline lineage does not.

A.0.41 Germline (vs somatic) intervention

A medical or biological modification that affects the gametes or early embryo and is therefore heritable, as distinct from a somatic intervention that affects only the body of the treated individual. The contemporary regulatory architecture, including the ISSCR guidelines, maintains a categorical bar on clinical germline modification. See Chapter 14.

A.0.42 Gerogene

A gene or pathway whose activity promotes ageing — the geroscience analogue of an oncogene. Identifying gerogenes is central to the move from a descriptive hallmark to a druggable target.

A.0.43 Geroprotector

An intervention, typically a drug or compound, that slows ageing or extends healthy lifespan by acting on one or more hallmarks. Rapamycin, metformin and the senolytics are leading candidates examined in Part III.

A.0.44 Geroscience

The hypothesis and research programme holding that, because ageing is the principal shared risk factor for chronic disease, targeting ageing directly can delay many diseases at once.

A.0.45 Gerosuppressor

A gene or pathway whose activity restrains ageing — the analogue of a tumour-suppressor. Loss of gerosuppressor function is expected to accelerate ageing, making such pathways targets for activation rather than inhibition.

A.0.46 Gompertz law

The empirical regularity that adult human mortality rises roughly exponentially with age; summarised by the mortality-rate doubling time (about eight years in humans).

A.0.47 Hallmarks of ageing

A set of interconnected cellular and molecular processes (twelve in the 2023 framework) that together characterise and drive ageing. See Chapter 2.

A.0.48 Healthspan

The portion of life lived in good health, free of serious disease and disability — to be distinguished from lifespan, total years lived.

A.0.49 Healthy life expectancy (HALE)

The average number of years a person can expect to live in “full health” given prevailing mortality and disability rates, computed by Sullivan’s method from period life tables and the disability burden of the Global Burden of Disease study. Reported at birth and at age 60. The principal summary measure of population health that combines longevity and quality of life. See Chapter 13.

A.0.50 Heterochromatin

Tightly packed, transcriptionally silenced chromatin (as opposed to open euchromatin), marked by modifications such as H3K9me3 and bound by proteins such as HP1a. Its progressive loss with age derepresses silenced sequences, including transposable elements.

A.0.51 Histone code

The combinatorial pattern of chemical modifications (acetylation, methylation and others) on histone proteins that opens or closes the wrapped DNA to transcription — a layer of regulatory information laid over the genome.

A.0.52 Immunosenescence

The age-related remodelling and decline of the immune system, which both weakens defence against infection and impairs the clearance of senescent and damaged cells, feeding chronic inflammation.

A.0.53 Inflammageing

The chronic, sterile, low-grade inflammation that rises with age in the apparent absence of infection; recognised as a hallmark in 2023. It links cellular senescence, through the SASP, to systemic age-related disease.

A.0.55 Insulin/IGF-1 signalling (IIS)

The conserved pathway through which insulin and insulin-like growth factor 1 report the availability of glucose and growth signals, driving anabolic, growth-promoting programmes. Genetically reduced IIS extends lifespan across species, and variants in its effector FOXO3 are linked to human longevity.

A.0.56 Integrative hallmarks

The top tier of the framework — the culprits of the visible ageing phenotype, emerging once damage overwhelms homeostatic capacity: stem-cell exhaustion, altered intercellular communication, chronic inflammation and dysbiosis.

A.0.57 Intermittent fasting

Any dietary pattern that alternates periods of normal eating with periods of little or no energy intake — for example alternate-day fasting or the 5:2 regimen — as distinct from a continuous reduction in daily calories.

A.0.58 Long-term care (LTC)

The set of personal and medical services provided to people who require assistance with the activities of daily living over a sustained period, typically in late life. Distinguished from acute medical care by its duration and its mixed health-and-social character; the source of the largest gap between need and provision in most ageing societies. See Chapter 13.

A.0.59 Longevity dividend

The aggregate welfare gain that would accompany a population-wide postponement of biological ageing, computed as the value of the additional healthy years produced rather than as observed GDP. Originally proposed by Olshansky and colleagues in 2006; quantified in trillions of dollars by microsimulation (Goldman et al., 2013) and welfare-economic (Scott et al., 2021; Scott et al., 2023) approaches. The dividend is a counterfactual welfare measure conditional on a successful slowdown, not a forecast of revenue. See Chapter 13.

A.0.60 Macroautophagy

The principal form of autophagy, in which a cell encloses worn organelles and proteins in a vesicle for digestion and recycling. Its age-related decline became a hallmark in its own right in 2023; enhancing it extends lifespan in model organisms.

A.0.61 Mesenchymal drift (MD)

A pervasive, organ-crossing tendency for differentiated cells to switch on mesenchymal gene programmes with age, eroding their specialised identity; reversible, in animal models, by partial reprogramming.

A.0.62 Myeloid skewing

The age-related bias of blood production away from the lymphoid lineages (which defend against new pathogens) towards the myeloid lineages (which drive inflammation); a hallmark of haematopoietic stem-cell exhaustion and a contributor to inflammageing.

A.0.63 Mitohormesis

The adaptive, protective response triggered by mild mitochondrial stress, by which a small dose of damage strengthens a cell’s resilience. It is the reason mitochondrial dysfunction is an antagonistic rather than a purely harmful hallmark.

A.0.64 Mitophagy

The selective autophagic clearance of damaged or surplus mitochondria — a quality-control mechanism that culls failing organelles. Its decline with age contributes to the accumulation of dysfunctional mitochondria.

A.0.65 mTOR (mechanistic target of rapamycin)

A central nutrient- and energy-sensing kinase; its complex mTORC1 responds to amino acids and energy to drive protein synthesis and growth and to suppress autophagy. Inhibiting mTOR (for example with rapamycin) extends lifespan in diverse organisms.

A.0.66 Multimorbidity

The co-occurrence of two or more chronic conditions in one individual, characteristic of later life. Its delayed onset is the composite endpoint on which geroscience-guided trials such as TAME are built, on the premise that an intervention against ageing should postpone many age-related diseases together. See Chapter 10.

A.0.67 Multiplicity

The statistical fact that performing many tests on the same dataset increases the probability that at least one will reach significance by chance, irrespective of any true effect. Protections include limiting the number of pre-specified primary endpoints, formal adjustment of significance thresholds (Bonferroni, Benjamini–Hochberg), and the public deposit of an analysis plan before the data are examined.

A.0.68 Multipotency

The capacity of an adult stem cell to produce a limited family of related cell types, such as the blood-forming stem cell and its descendants. The decline of these stem cells with age is the hallmark known as stem-cell exhaustion.

A.0.69 NAD⁺ (nicotinamide adenine dinucleotide)

A central metabolic cofactor that both carries electrons in energy metabolism and is consumed as a substrate by enzymes including the sirtuins, PARPs and CD38. Tissue NAD⁺ declines with age, weakening the processes that depend on it.

A.0.70 Normal-function account

The view, due principally to Christopher Boorse and developed in medical ethics by Norman Daniels, that disease is a deviation from species-typical statistical function in a biological system, and that the proper task of medicine is to restore that normal function. The basis on which one variant of the therapy/enhancement distinction is drawn. See Chapter 14.

A.0.71 Nuclear (3D) genome organisation

The spatial folding of the genome — into lamina-associated domains, topologically associating domains and compartments — that brings regulatory elements to their target genes and insulates active from silent regions. Its erosion is a feature of the ageing epigenome.

A.0.72 Old-age dependency ratio

A demographic measure of the relative size of the older population, conventionally the number of people aged 65 and over per 100 people of working age (15–64). A crude instrument — it classifies by age rather than by functional capacity — but a reliable indicator of the changing balance between those who typically draw on, and those who typically fund, pensions and care. See Chapter 12.

A.0.73 Oncogene-induced senescence (OIS)

The senescence triggered when an activated oncogene drives aberrant proliferation — a fail-safe that halts cells at risk of transformation, mediated largely by the p16INK4a and p53 tumour-suppressor pathways.

A.0.74 Organoid

A self-organising, three-dimensional miniature of an organ grown from stem cells, reproducing enough of its structure and function to model development, disease and drug responses — and, increasingly, proposed as a transplantable building block for repair.

A.0.75 Out-of-pocket payments (OOP)

Direct payments made by households at the point of using a health service, net of any reimbursement by a third-party payer. The share of total health spending borne as OOP is one of the strongest predictors of catastrophic or impoverishing health expenditure and a primary signal of failing financial protection. See Chapter 13.

A.0.76 Paracrine signalling

Communication in which a cell secretes signals that act on neighbouring cells, rather than on itself (autocrine) or at a distance through the bloodstream (endocrine). The paracrine hypothesis holds that much of a transplanted stem cell’s benefit comes from what it secretes — its secretome — rather than from lasting engraftment.

A.0.77 Partial reprogramming

The transient or cyclic application of reprogramming factors to restore youthful gene-expression patterns without converting a cell fully into a stem cell. See Chapter 8.

A.0.78 Pluripotency

The capacity of a cell to give rise to all the cell types of the body; the embryonic-like state reached by full reprogramming.

A.0.79 Precision geromedicine

The proposed clinical translation of geroscience: matching ageing-directed interventions to an individual’s molecular profile, by analogy with precision oncology, targeting their specific gerogenes and gerosuppressors.

A.0.80 Pre-registration

The public lodging of a study’s hypothesis, design and analysis plan before the data are collected or seen. Pre-registration separates exploratory analysis (which is legitimate) from confirmatory analysis (which is what carries evidential weight), and is the principal protection against undisclosed flexibility in how a result is reached. Standard for high-quality trials; widely available for observational and pre-clinical work.

A.0.81 Primary hallmarks

The foundational tier of the framework — the unambiguous causes of cellular damage that accumulate with time: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis and disabled macroautophagy.

A.0.82 Principle of Humanity

Nicholas Agar’s proposed constraint on enhancement: in choosing among possible enhancements, defer to the considered judgement of unenhanced humans about what is valuable in being human, and prefer the moderate to the radical and the reversible to the irreversible. See Chapter 15.

A.0.83 Principle of Procreative Beneficence (PB)

The welfarist principle, formulated by Julian Savulescu and Guy Kahane, that couples who decide to have a child have a significant moral reason to select, among the children they could have, the one whose life can be expected to go best. A central reference point in the ethics of reproductive selection and the welfarist treatment of enhancement. See Chapter 14.

A.0.84 Proteostasis

The maintenance of a healthy complement of correctly folded proteins, through synthesis, folding, and degradation; its decline is a hallmark of ageing.

A.0.85 Prudential lifespan account

The framework proposed by Norman Daniels in Just Health for thinking about the allocation of health resources across the life course as the choice a prudent person would make under uncertainty about which life stage they would occupy. Reframes intergenerational equity from a contest between age groups into a question about the trajectory of a single life. The reference framework for normative discussion of who gets geroprotective therapies first (Daniels, 2008). See Chapter 13.

A.0.86 Scaffold (tissue engineering)

A three-dimensional support, natural or synthetic, that provides cells with the architecture and mechanical cues needed to organise into a functional tissue. A decellularised organ is one kind of scaffold.

A.0.87 Secretome

The full set of molecules a cell secretes — growth factors, cytokines and extracellular vesicles. Increasingly regarded as the active principle of stem-cell therapy, and the basis of cell-free treatments that use the secretions in place of the cells.

A.0.88 Senescence-associated secretory phenotype (SASP)

The mixture of inflammatory and tissue-remodelling molecules secreted by many senescent cells, through which they affect neighbouring tissue.

A.0.89 Senescent-cell anti-apoptotic pathway (SCAP)

One of the pro-survival signalling networks (including the BCL-2 protein family, the PI3K–AKT axis and certain dependence receptors) that a senescent cell must keep active to resist its own apoptotic pressure. Because the dependency is largely specific to senescent cells, transiently disabling a SCAP is the basis of most senolytic drugs. See Chapter 7.

A.0.90 Senomorphic

A drug or agent that suppresses the harmful secretions of a senescent cell — above all the SASP — without killing the cell. Unlike a senolytic, which subtracts the cell, a senomorphic only silences it, so its effect is reversible and typically requires continuous dosing. See Chapter 7.

A.0.91 Senolytic

A drug or agent that selectively kills senescent cells (as opposed to a senomorphic, which suppresses their secretions). Senolytics are typically given intermittently; see Chapter 7.

A.0.92 Shelterin

The protein complex that binds telomeric DNA, forms the protective end-loop and shields the chromosome end from being read as a double-strand break. Loss of shelterin function ages tissues even when telomere length is normal.

A.0.93 Sirtuin

One of a family of NAD⁺-dependent enzymes (SIRT1–7 in mammals) that deacetylate target proteins, linking the cell’s energy state to DNA repair, chromatin regulation and mitochondrial function. Sirtuin activity is associated with extended lifespan.

A.0.94 Species relativism

The thesis, associated with Nicholas Agar, that judgements of value are made relative to the kind of being making them, so that the good life of a radically enhanced descendant is incommensurable with — neither better nor worse than — that of an unenhanced human. See Chapter 15.

A.0.95 Stem-cell niche

The specialised local microenvironment that houses a stem cell and signals whether it should rest, self-renew or differentiate. Ageing of the niche, not only of the stem cell itself, contributes to the failure of tissue renewal in later life.

A.0.96 Stem-cell exhaustion

The age-related decline in the number and function of the stem cells that renew tissues; an integrative hallmark and a principal reason ageing tissues repair and regenerate poorly. See Chapter 9.

A.0.97 Surrogate endpoint

A marker substituted for a true clinical outcome (such as disease onset or death) in a trial, on the understanding that changing it reliably changes the outcome. A valid surrogate must lie on the causal path from intervention to outcome; many biomarkers of ageing correlate with the outcome without meeting this standard. See Chapter 10.

A.0.98 Target trial emulation

A method of causal inference in which the randomised trial one would ideally run is specified in full — eligibility, treatment strategies, outcome and analysis — and then approximated using observational data, making explicit the assumptions a naïve analysis would otherwise leave hidden. See Chapter 10.

A.0.99 Telomerase

The reverse-transcriptase enzyme (catalytic subunit TERT) that rebuilds telomeres by adding repeat sequence to chromosome ends. Active in germ, stem and cancer cells; silenced in most somatic cells, which therefore age replicatively.

A.0.100 Telomere

A protective repetitive cap at the end of a chromosome that shortens with each cell division; its erosion underlies the replicative (Hayflick) limit. See Chapter 4.

A.0.101 Telomeropathy (short-telomere syndrome)

A disease caused by inherited deficiency in telomerase or shelterin, producing premature failure of high-renewal tissues — including pulmonary fibrosis, dyskeratosis congenita and aplastic anaemia.

A.0.102 Teratoma

A tumour containing tissues from all three embryonic germ layers, arising when cells reach or approach pluripotency in the body. Its formation is the defining hazard of in-vivo reprogramming and the reason rejuvenation protocols stop short of full reprogramming. See Chapter 8.

A.0.103 Therapeutic misconception

The tendency of research participants to interpret their participation in a clinical trial as the receipt of a therapeutic intervention rather than as a contribution to a research enterprise. Identified by Paul Appelbaum and colleagues; particularly acute in trials of interventions for ageing, where the participant has a personal stake in the outcome. See Chapter 14.

A.0.104 Time-restricted eating

A form of intermittent fasting that confines food intake to a limited window of the day (commonly around eight hours), leaving a prolonged daily fast, with benefits that appear to depend partly on alignment with the circadian cycle.

A.0.105 Total fertility rate (TFR)

The average number of children a woman would bear over her lifetime if she experienced the prevailing age-specific fertility rates throughout her childbearing years. A TFR of about 2.1 in low-mortality settings is the replacement level at which each generation exactly replaces the one before; sustained values below it imply long-run population decline in the absence of migration.

A.0.106 Totipotency

The capacity of a single cell — the fertilised egg and its very earliest descendants — to generate an entire organism, extra-embryonic tissues included. It is the maximal developmental potential, from which every later cell progressively narrows.

A.0.107 Transcriptomic clock

An estimator of biological age and mortality risk built from patterns of gene expression rather than DNA methylation, allowing the contributing biological processes to be read more directly than methylation clocks permit.

A.0.108 Transdifferentiation

The direct conversion of one specialised cell type into another without passing through a stem-like state. Of growing interest in regenerative medicine, it is further proof that cell identity, though normally stable, is not fixed for ever.

A.0.109 Transhumanism

The intellectual and cultural movement that welcomes the radical enhancement of human capacities as a desirable next stage of human development. To be distinguished from human enhancement as a practice, which may be defended or opposed without commitment to the movement’s aims.

A.0.110 Transposable element

A mobile or formerly mobile DNA sequence, such as LINE-1, normally locked within heterochromatin. Its reactivation in aged cells triggers innate-immune sensing and sterile inflammation, linking epigenetic decay to inflammageing.

A.0.111 Value of statistical life (VSL)

The monetary value placed on the marginal reduction in mortality risk in a population, derived empirically from observed trade-offs (in labour markets, in consumer markets) between income and small risk reductions. The standard input that converts a quantitative health gain into a welfare-equivalent monetary figure in cost-benefit analyses of public health interventions, including the calculation of the longevity dividend.

A.0.112 Waddington’s epigenetic landscape

A classic metaphor in which a developing cell is a ball rolling downhill into one of many valleys, each a stable mature fate. Reprogramming pushes the ball back uphill; ageing, in the information view, is the ball slowly drifting out of its valley.

A.0.113 Xenotransplantation

The transplantation of cells, tissues or organs from one species to another — in practice, organs from gene-edited pigs into humans, with the animal’s antigens engineered away to limit rejection. A nearer-term rival to blastocyst complementation for the organ shortage. See Chapter 9.

A.0.114 XT9T (ICD-11 “ageing-related” extension code)

An extension code in the eleventh revision of the International Classification of Diseases, located in the “Causality” chapter, which allows clinicians and researchers to designate a condition as ageing-related without committing to the position that ageing is itself a disease. Introduced following the submission of Khaltourina et al. (2020). The institutional compromise between two opposed positions on the nosology of ageing. See Chapter 14.

A.0.115 Yamanaka factors (OSKM / OSK)

The transcription factors Oct4, Sox2, Klf4 and c-Myc (OSKM; the safer subset omits c-Myc, giving OSK) that can reprogram a specialised cell towards pluripotency, and in pulses can partially reverse cellular age.